Human Cloning is one of those issues where technology is racing well ahead of contemporary morals and ethical frameworks. Xu Xiaochun, the chief executive behind the world’s biggest cloning factory – Boyalife Group – has stated that at this moment, the technology to clone humans is already available, and that they are refraining from using it for fear of public reaction.
The giant cloning facility is set to open within the next seven months, and they aim to have a yearly output of one million cloned cows per year. Not only that, they are also already looking to clone thoroughbred racehorses as well as police and pet dogs specialized in sniffing and searching. Some people are even willing to pay to bring a deceased pet back to life. But, more notable, is the research that Boyalife is conducting with its South Korean partner Sooam and the Chinese Academy of Sciences. They are trying to improve the capacity for cloning primates, to create better test animals for disease research. And guess who’s a primate too? That’s right, we are!
Xu Xiaochun stated: “The technology is already there. If this is allowed, I don’t think there are other companies better than Boyalife that make better technology”.
So, maybe, the biological premise that restrains each individual to having half of its genetic material come from a mother and the other half from a father may cease being the only option. A third choice may arise, where the child is one hundred percent either its father or its mother.
Even though we may have many, culturally justified moral problems with the issue of cloning, we can be sure of one thing. With time, they will disappear. Boyalife knows that, and they are simply waiting for that moment. In the same way a computer would have looked like demon magic to one of our paleolithic ancestors, cloning seems so strange and far away to us. But in a future maybe not too far away, it will not – it will be progress. O brave new world, that has such people in ‘t!
Boyalife, Science & Science Translational Medicine Award in Stem Cells and Regenerative Medicine
-- Notice: This Award Has Been Discontinued --
About the Prize
Science/AAAS and Science Translational Medicine have joined efforts with Boyalife to present the Award in Stem Cell and Regenerative Medicine. This annual prize will focus on research in the field of stem cells and regenerative medicine. Each year, a grand prize winner will receive a prize of US$25,000 and a runner-up will receive a prize of US$5,000. The grand prize winning essay and brief abstract of the runner-up essay will be published in Science. Both awardees will receive a 5-year AAAS membership including a subscription to Science.
Boyalife Group, previously known as the International Consortium of Stem Cell Research (INCOSC), was founded in July 2009 in Wuxi, China. INCOSC was initially formed as an industrial-research among seven of the world’s top research institutes in life sciences and medicine, including Peking University, the Chinese Academy of Sciences, Roslin Institute, Scottish Center for Regenerative Medicine. INCOSC aimed to accelerate translation of biomedical research into clinical applications. This initiative was directly supported by two major grants from Chinese Ministry of Science & Technology (2010DFB30640). INCOSC later become Boyalife Group.
Currently, Boyalife Group has over 30 subsidiaries and nationwide operation. Among all the subsidiaries, the Boyalife Stem Cell Bank is the nation’s leading clinical stem cell bank, accredited by American Association of Blood Banking (AABB) and World Health Organization. In July 2015, the Boyalife became the world’s first Stem Cell Bank accredited by AABB standard of Somatic Cell. Through other subsidiaries, the company is also engaged in regenerative medicine, genomics, animal cloning, innovative drug discovery and disease modeling.
In 2012, Boyalife Group won the prestigious “2012 CCTV China Brand Award”, becoming the leading brand in healthcare and pharmaceutical sector in China.
The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society, and publisher of the journals, Science, Science Translational Medicine, Science Signaling and Science Advances. AAAS was founded in 1848, and includes some 254 affiliated societies and academies of science, serving 10 million individuals. Science, founded by Thomas Edison, has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 570,400.
The non-profit AAAS -- www.aaas.org -- is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy, international programs, science education, and more. Science's daily online news is always free to the public, as are editorials, any paper with broad public health significance, and all research articles 12 months after publication. Science further participates in various efforts to provide free access for scientists in the world's poorest countries.
About Science Translational Medicine
Science Translational Medicine publishes original, peer-reviewed, science-based research articles that report successful advances toward the goal of improving patients' lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts hold Science Translational Medicine articles to the same high-quality standard that is the hallmark of the journal Science.
Its mission is to promote human health by providing a forum for communication and cross-fertilization among basic, translational, and clinical research practitioners and trainees from all relevant established and emerging disciplines.